Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted
Executive Summary
Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.